ADHD. Attention-deficit hyperactivity disorder, combined type
Conditions
Interventions
Intervention 1: Intervention group: Agomelatine (Agolyp 25mg tablet), a product of Tadbir Kala Jam Pharmaceutical Company, is administered at a starting dose of 12.5mg daily for patients weighing at l
Sponsors
Zanjan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
8 Years to 18 Years
Inclusion criteria
Inclusion criteria: 8 to 18 years ADHD disorder based on DSM5 criteria Children with a partial response to Ritalin such that symptoms such as anxiety and mood symptoms remain Normal IQ based on doctor's judgment Minimum weight 30 kilograms
Exclusion criteria
Exclusion criteria: Children who have received Ritalin in the past and have not shown a positive therapeutic response and effectiveness. Interfering physical disorders include: neurological disorders, history of severe hypersensitivity reaction to agomelatine, history of heart disease. A history of major psychiatric illnesses (mood and suicidal ideation disorders, psychotic disorders, substance abuse). Recent use of anti-anxiety and antidepressant medication within the past 2 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptoms of Attention Deficit Hyperactivity Disorder (ADHD). Timepoint: At baseline, week 4, and week 8. Method of measurement: Conners’ Rating Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed AbdolSamad Mazloomi
Zanjan University of Medical Sciences
Outcome results
None listed